C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/22 (2006.01) A61K 39/395 (2006.01) A61P 11/06 (2006.01) A61P 13/12 (2006.01) A61P 27/02 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01) G01N 33/577 (2006.01)
Patent
CA 2370304
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF.beta.1 and are useful in treating conditions associated with excess TGF.beta.1 activity, such as fibrosis, immune responses and tumour progression.
La présente invention concerne des éléments de liaison spécifiques, par exemple sous forme de domaines variables d'anticorps, basés sur des séquences CDR3 des régions VH d'anticorps de SL15 (SEQ ID NO:4) et de JT182 (SEQ ID NO:10). Ces anticorps présentent une forte activité neutralisante pour TGF.beta.1 et ils sont utilisés pour traiter les états associés à la suractivité de TGF.beta.1, comme les fibroses, les réponses immunes et la progression tumorale.
Braddock Peta Sally Helena
Conroy Louise Anne
Du Fou Sarah Leila
Lennard Simon Nicholas
Mccafferty John Gerald
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Cambridge Antibody Technology Limited
LandOfFree
Specific antibodies and antibody fragments for tgf.beta.1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific antibodies and antibody fragments for tgf.beta.1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific antibodies and antibody fragments for tgf.beta.1 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1898291